MedTrace Logo

Prophylactic Treatment of Episodic Cluster Headache

NCT00184587 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-04-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether candesartan cilexetil are effective prophylactic treatment of episodic Cluster headache

Conditions

  • Cluster Headache

Interventions

DRUG

candesartan cilexetil

DRUG

placebo

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Norwegian University of Science and Technology

    lead OTHER

Principal Investigators

  • Lars J Stovner, PhD · Norwegian National Headache Center St.Olavs Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2009-06-30
Completion
2009-12-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00184587 on ClinicalTrials.gov